Finally, after nearly two decades, Exelixis (Nasdaq: EXEL ) has received approval from the Food and Drug Administration for its first drug, cabozantinib. Now called Cometriq, it is used to treat advanced medullary thyroid cancer once the disease has spread to other organs. However, in this video, Motley Fool health care analyst David Williamson gives reasons to temper enthusiasm over this approval while keeping an eye on future clinical trial results for cabozantinib in prostate cancer.
Of course, prostate cancer treatment is becoming an increasingly crowded space. Take for instance Dendreon's run over the past four years. Investors witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine Provenge became a lightning rod of debate. But where does that leave investors -- other than a bit nauseous from the roller-coaster ride? Our own David Williamson answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.